BYSI - BeyondSpring Inc.
| Previous Close | 16.05 |
| Open | 16.20 |
| Bid | 16.27 x 3000 |
| Ask | 16.34 x 1400 |
| Day's Range | 15.77 - 16.45 |
| 52 Week Range | 13.06 - 26.98 |
| Volume | 88,212 |
| Avg. Volume | 67,231 |
| Market Cap | 390.375M |
| Beta (3Y Monthly) | 1.39 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.12 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 41.00 |
- GlobeNewswire•3 days ago
BeyondSpring Announces Pricing of Public Offering of Ordinary Shares
BeyondSpring Inc. (the “Company” or “BeyondSpring”) (BYSI), a global clinical stage biopharmaceutical company focused on the development and commercialization of innovative immuno-oncology cancer therapies, today announced the pricing of its public offering of 2,058,825 ordinary shares at a public offering price of $17.00 per share. The offering was led by Decheng Capital. The gross proceeds from the public offering are expected to be $35.0 million, before deducting underwriting discounts and commissions and other offering expenses.
- GlobeNewswire•4 days ago
BeyondSpring Announces Proposed Public Offering of Ordinary Shares
BeyondSpring Inc. (the “Company” or “BeyondSpring”) (BYSI), a global clinical stage biopharmaceutical company focused on the development and commercialization of innovative immuno-oncology cancer therapies, today announced that it plans to launch an underwritten public offering of its ordinary shares. The offering is being led by Decheng Capital LLC. The Company also expects to grant the underwriter an option to purchase up to an additional 15% of the ordinary shares being offered to cover over-allotments. The Company intends to use the net proceeds of this offering to support continued clinical and pre-clinical development and for general corporate purposes.
- GlobeNewswire•10 days ago
BeyondSpring Provides Operational Update and First Quarter 2019 Financial Results
- New and Compelling Plinabulin Data Presented at Key Scientific Conferences - - To Submit New Drug Applications (NDAs) in China for Both Non-Small Cell Lung Cancer (NSCLC) and.
- Benzinga•22 days ago
18 Stocks Joining The Russell Indices
The Russell 2000 Index is a small-cap stock market index that includes the bottom 2,000 companies found in the Russell 3000 index. The Russell Microcap Index includes the 1,000 smallest securities found ...
- GlobeNewswire•last month
BeyondSpring Set to Join FTSE Russell 3000® Index
BeyondSpring Inc. (BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, announced today that it will join the FTSE Russell 3000® Index at the conclusion of the 2019 Russell indexes annual reconstitution, effective after the U.S. market opens on July 1, 2019, according to a preliminary list of additions posted June 7, 2019. Membership in the Russell 3000® Index, which remains in place for one year, means the automatic inclusion of BeyondSpring common stock in index funds designed to track stocks included in the Russell 3000® Index. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.
- GlobeNewswire•2 months ago
BeyondSpring to Present at the Jefferies 2019 Healthcare Conference
BeyondSpring Inc. (BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, announced today that management will provide a corporate overview at the Jefferies 2019 Healthcare Conference in New York, NY on Friday, June 7, 2019, at 9:00 a.m. Eastern Time. BeyondSpring is a global, clinical-stage biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies. BeyondSpring’s lead asset, Plinabulin, is in a Phase 3 global clinical trial as a direct anticancer agent in the treatment of non-small cell lung cancer (NSCLC) and two Phase 2/3 clinical programs in the prevention of chemotherapy-induced neutropenia (CIN).
- GlobeNewswire•2 months ago
BeyondSpring Abstract Demonstrating Bone Pain Benefit with Lead Asset, Plinabulin, versus Neulasta for Neutropenia Prevention Presented at ISPOR 2019
BeyondSpring Inc. (BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that the Company’s abstract on its lead asset, Plinabulin, has been accepted for poster presentation at the ISPOR (International Society for Pharmacoeconomics and Outcomes Research) 2019 Conference. ISPOR is internationally recognized as the leading educational and scientific organization for health economics and outcomes research (HEOR) and its use in healthcare decisions. The data, derived from BeyondSpring’s Phase 2 Study 105, shows that Plinabulin at 20mg/m2 has a similar efficacy profile in reducing docetaxel-induced neutropenia as Neulasta 6mg (pegfilgrastim, the current standard of care), with the added safety benefit of avoiding the patient-reported bone pain that’s typically observed with Neulasta.
- GlobeNewswire•2 months ago
BeyondSpring’s Rationale for the Plinabulin-Neulasta Combination for Neutropenia Prevention Accepted as Abstracts at 2019 ASCO Annual Meeting
BeyondSpring Inc. (BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that two of the Company’s abstracts on its lead asset, Plinabulin, have been accepted for publication in the Proceedings of this year’s ASCO Annual Meeting. The data, derived from BeyondSpring’s Phase 2 Study 106, provides a strong rationale for the Plinabulin Neulasta (pegfilgrastim) combination for the prevention of chemotherapy-induced neutropenia (CIN) for improved CIN control.
- GlobeNewswire•3 months ago
BeyondSpring Files 2018 Annual Report on Form 20-F
NEW YORK, April 30, 2019 -- BeyondSpring Inc. (NASDAQ:BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that.
Motley Fool•3 months agoBeyondSpring Inc. (BYSI) Q4 2018 Earnings Call Transcript
BYSI earnings call for the period ending December 31, 2018.
- GlobeNewswire•3 months ago
BeyondSpring Provides Business Update and Fourth Quarter and Full-Year 2018 Financial Results
- Significant Clinical Data Generated for Plinabulin - - On Track to Submit New Drug Applications (NDAs) for Plinabulin to China’s National Medical Products Administration.
- ACCESSWIRE•3 months ago
BeyondSpring, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / April 30, 2019 / BeyondSpring, Inc. (NASDAQ: BYSI ) will be discussing their earnings results in their 2018 Third Quarter Earnings to be held on April 30, 2019 at 8:00 AM Eastern ...
- GlobeNewswire•3 months ago
BeyondSpring to Host Fourth-Quarter and Full-Year 2018 Financial Results and Operational Update Conference Call on April 30, 2019
BeyondSpring Inc. (BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that the Company will report fourth-quarter and full-year 2018 financial results and host an operational and clinical update conference call on Tuesday, April 30, 2019, at 8:00 a.m. Eastern Time. BeyondSpring is a global, clinical-stage biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies. BeyondSpring’s lead asset, Plinabulin, is in a Phase 3 global clinical trial as a direct anticancer agent in the treatment of non-small cell lung cancer (NSCLC) and two Phase 2/3 clinical programs in the prevention of chemotherapy-induced neutropenia (CIN).
- GlobeNewswire•4 months ago
BeyondSpring to Present at the 18th Annual Needham Healthcare Conference
BeyondSpring Inc. (BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, announced today that management will provide a corporate overview at the 18th Annual Needham Healthcare Conference on Tuesday, April 9, 2019, at 8:00 a.m. Eastern Time at the Westin Grand Central Hotel in New York, NY. BeyondSpring is a global, clinical-stage biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies. BeyondSpring’s lead asset, Plinabulin, is in a Phase 3 global clinical trial as a direct anticancer agent in the treatment of non-small cell lung cancer (NSCLC) and two Phase 2/3 clinical programs in the prevention of chemotherapy-induced neutropenia (CIN).
- GlobeNewswire•4 months ago
BeyondSpring’s Lead Asset, Plinabulin, Shifts the Balance of Macrophages Towards Anti-Cancer M1s
BeyondSpring Inc. (BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, announced today that the Company will present a promising new strategy for cancer treatment involving the ability of lead asset, Plinabulin, to positively shift the balance of macrophage phenotypes for beneficial anti-cancer effect at the 2019 American Association for Cancer Research (AACR) Annual Meeting in Atlanta, Georgia. The results will be highlighted in a poster presentation titled, “Microtubule Destabilization by Plinabulin Generates Anti-Tumor Immune Response through Repolarization of Intratumoral Macrophages,” taking place on April 3rd from 8 a.m. to 12 p.m. local time.
- GlobeNewswire•4 months ago
BeyondSpring Advancing Patient Targeting Strategies for Lead Asset Plinabulin
BeyondSpring Inc. (BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, announced today that the Company will present novel data relevant to predictive biomarkers for patient selection for its lead asset, Plinabulin, at the 2019 American Association for Cancer Research (AACR) Annual Meeting in Atlanta, Georgia. The results from this non-clinical study will be highlighted in a poster presentation titled, “Predictive Models for Tumor Cell Targeting with Plinabulin, Derived from In Vitro Screening and Affymetrix mRNA Expression Data,” on April 1 from 8 a.m. to 12 p.m. local time.
- GlobeNewswire•4 months ago
BeyondSpring to Present Clinical Trial Data on Lead Asset, Plinabulin, at 2019 St. Gallen International Breast Cancer Conference
NEW YORK, March 20, 2019 -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that.
- GlobeNewswire•5 months ago
BeyondSpring Presents New Promising Data in Chemotherapy-Induced Neutropenia at 2019 ASCO-SITC Clinical Immuno-Oncology Symposium
BeyondSpring Inc. (BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, presented new clinical results from its Study 106 program in the prevention of chemotherapy induced neutropenia (CIN) for its lead asset Plinabulin at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium. The data showed that, through combining Plinabulin with Neulasta, patients not only experienced better outcomes for CIN treatment, but Neulasta’s potential immune-suppressive phenotype was also reduced.
- GlobeNewswire•5 months ago
New Data Shows Addition of BeyondSpring’s Plinabulin Reverses Neulasta’s Potential Immune-Suppressive Phenotype in Treating Chemotherapy-Induced Neutropenia
BeyondSpring Inc. (BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced new clinical results from its Study 106 program for lead asset Plinabulin, which demonstrates that combining Plinabulin with Neulasta (pegfilgrastim) not only improves overall efficacy for chemotherapy-induced neutropenia (CIN) treatment but also reverses Neulasta’s potential immune-suppressive phenotype. The data will be presented by Dr. Douglas Blayney, global Principal Investigator for BeyondSpring’s CIN development program and Professor of Medicine at Stanford University Medical Center, in a poster presentation titled, “A Phase II trial with the Combination of Plinabulin and Pegfilgrastim: Evaluation of the Reversal of Peg’s Immune-Suppressive Potential by the Addition of Plin to Peg,” at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium.
- GlobeNewswire•7 months ago
BeyondSpring Announces Positive Pre-NDA Meeting with the U.S. FDA for its Lead Asset, Plinabulin
BeyondSpring Inc. (BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that it had a positive pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration (FDA) regarding its lead asset, Plinabulin. The focus of this meeting was the content of the chemistry, manufacturing and control (CMC) sections of the Company’s planned NDAs for Plinabulin for the treatment of non-small cell lung cancer (NSCLC) and chemotherapy-induced neutropenia (CIN) prevention.
- GlobeNewswire•7 months ago
United States Patent and Trademark Office Issues Composition of Matter Patent with BeyondSpring’s Lead Asset Plinabulin with Protection to 2036
BeyondSpring Inc. (BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that the United States Patent and Trademark Office (USPTO) has issued the Company U.S. Patent No. 10,155,748 related to a new composition of matter of BeyondSpring’s lead asset, Plinabulin. This composition of matter patent is directed to Plinabulin’s monohydrate in a crystalline form and provides patent protection in the U.S. until 2036. “Adding yet another vital patent to BeyondSpring’s robust global intellectual property (IP) portfolio enables us to effectively maximize Plinabulin’s commercial potential across therapeutic indications, starting with chemotherapy-induced neutropenia (CIN) prevention and non-small cell lung cancer (NSCLC) treatment, followed by combinations with immunotherapies,” said Dr. Huang.
- GlobeNewswire•7 months ago
BeyondSpring Announces Phase 3 Study 105 of its Lead Asset Plinabulin for Chemotherapy-Induced Neutropenia Meets Primary Endpoint at Interim Analysis
BeyondSpring Inc. (BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that the Phase 3 portion of its pivotal Study 105, evaluating its lead asset, Plinabulin, in the 105 enrolled patients treated with docetaxel chemotherapy, has met its primary endpoint of non-inferiority versus Neulasta® for the duration of severe neutropenia (DSN) of the first cycle, with statistical significance in a pre-specified interim analysis. In this trial, Plinabulin as a single agent was compared head-to-head with Neulasta as a single agent.
- GlobeNewswire•7 months ago
Data for BeyondSpring’s Lead Asset, Plinabulin, for Chemotherapy-Induced Neutropenia (CIN) Prevention Shows Differentiated Profile Compared with G-CSF and Adds Additional Protection to G-CSF
Plinabulin monotherapy is an equally effective single-dose-per cycle agent as pegfilgrastim, but with minimal bone pain vs. pegfilgrastim in intermediate neutropenic risk.
- Zacks•8 months ago
Can The Uptrend Continue for BeyondSpring (BYSI)?
Investors certainly have to be happy with BeyondSpring Inc. (BYSI) and its short term performance.
